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Abstract
Yes‐associated protein (YAP) is a component of the canonical Hippo signaling path‐
way that is known to play essential roles in modulating organ size, development, and
tumorigenesis. Activation or upregulation of YAP1, which contributes to cancer cell
survival and chemoresistance, has been verified in different types of human cancers.
However, the molecular mechanism of YAP1 upregulation in cancer is still unclear.
Here we report that the E3 ubiquitin ligase STUB1 ubiquitinates and destabilizes
YAP1, thereby inhibiting cancer cell survival. Low levels of STUB1 expression were
correlated with increased protein levels of YAP1 in human gastric cancer cell lines
and patient samples. Moreover, we revealed that STUB1 ubiquitinates YAP1 at the
K280 site by K48‐linked polyubiquitination, which in turn increases YAP1 turnover
and promotes cellular chemosensitivity. Overall, our study establishes YAP1 ubiqui‐
tination and degradation mediated by the E3 ligase STUB1 as an important regula‐
tory mechanism in gastric cancer, and provides a rationale for potential therapeutic
interventions.
KEYWORDS

chemoresistance, gastric cancer, STUB1, ubiquitination, YAP1

Abbreviations: CHX, cycloheximide; GC, gastric cancer; HSP, heat shock protein; STUB1, carboxy terminus of Hsc70 interacting protein; TPR, tetratricopeptide repeat; YAP1,
Yes‐associated protein.
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1 | I NTRO D U C TI O N
Although the incidence of malignant GC declined in many devel‐
oped countries from the 1940s to the 1980s, this cancer remains

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Cell culture, constructs, and Abs

a major public health problem throughout the world, as it is the

HEK293T cells and the human GC cell lines SGC7901, MGC803,

most common malignant gastrointestinal cancer, especially in East

MKN45, 9811P, HGC27, BSG823, MKN28, AGS, and BGC803 were

Asia,1 and causes 12% of all cancer‐related deaths each year. 2

purchased from the National Infrastructure of Cell Line Resources

Over 95% of gastric tumors are adenocarcinomas histologically

of China. All cell lines were tested and authenticated by karyotyp‐

classified as either intestinal or diffuse type. 3 Gastric cancer is

ing analysis on 1 January 2018, and confirmed by the National

a multifactorial and multistep disease that involves activation of

Infrastructure of Cell Line Resources of China. Expression plas‐

oncogenes and inactivation of tumor suppressor genes during GC

mids containing pCMV‐Flag‐STUB1, pCMV‐Myc‐STUB1, pCMV‐

progression.4 Studies have found that inactivation of Hippo signal‐

Flag‐YAP1, and pCMV‐Myc‐YAP1 were constructed as previously

ing leads to proproliferative and antiapoptotic signaling associated

described, 20 and the different Flag‐tagged STUB1 fragments and

with increased cancer risk. 5-9

mutations were generated as previously described. 21 The HA‐tagged

As a key downstream effector, YAP1 plays a key role in

ubiquitin (HA‐ub) plasmid and mutation constructs were kindly pro‐

the Hippo pathway to control cell proliferation and growth.

vided by Professor Jianfei Qi from the University of Maryland Cancer

Dysregulation of the Hippo/YAP1 pathway is involved in cancer

Center. Mutations were produced using a QuikChange Site‐Directed

10

development.

Elevated YAP1 activity and/or YAP1 overexpres‐

Mutagenesis Kit (Stratagene) and validated by DNA sequencing.

sion has been observed in a subset of primary human cancers,11

The anti‐STUB1 (C3B6) rabbit mAb #2080, the anti‐YAP1 (D24E4)

and elevated YAP1 protein expression and nuclear localization are

rabbit mAb #8418, and anti‐HSP90 (C45G5) rabbit mAb #4877 were

correlated with poor prognosis.12-15 The activity of YAP1 is tightly

purchased from Cell Signaling Technology. Anti‐ub (sc‐8017) Abs

governed by posttranslational modification. Several studies have

were purchased from Santa Cruz Biotechnology. Antibodies against

elucidated that a deubiquitinase, DUB3, regulates YAP/TAZ ac‐

HA (H9658), FLAG (F1804), and β‐actin (A1978) were purchased

tivity by controlling the stability of the E3 ligase ITCH, the LATS

from Sigma. The HSP90 inhibitor 17‐AAG was purchased from Cell

kinases and the AMOT family proteins.16 Recently, it was reported

Signaling Technology (8132S) and used at 10 μmol/L.

that the deubiquitination enzyme USP9X deubiquitinates and sta‐
bilizes YAP1, thereby promoting cancer cell survival.10 In addition,
YAP1 can be regulated by other posttranslational modification.
Lats and CK1 coordinately phosphorylate YAP1 and subsequently

2.2 | Cell survival assay
Gastric cancer cell lines stably expressing the indicated constructs

recruit the SCF (beta‐TRCP) E3 ubiquitin ligase, which catalyzes

were incubated for 24 hours and were then treated with mitomy‐

YAP1 ubiquitination, ultimately leading to YAP1 degradation.17 A

cin, cisplatin, or etoposide at the indicated doses. After 36 hours,

recent study found that Fbxw7 regulated YAP1 protein abundance

the 96‐well plates were read in an Epoch2 microplate reader (BioTek

by targeting YAP1 for ubiquitination and proteasomal degradation

Instruments). The cell survival ratio calculated by 3‐(4,5‐dimethyl‐

18

in hepatocellular carcinoma.

Thus, the role of YAP1 as a prom‐

ising and important therapeutic target has been increasingly rec‐

thiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenyl)‐

2H‐

tetrazolium assay (Promega).

ognized. However, research regarding specific YAP1 inhibitors and
their potential therapeutic use in cancers remains very limited,
with only a few reports to date, limited to small‐molecule inhibi‐
tors.19 Therefore, there is a great need to identify new prognostic

2.3 | Soft agar colony formation assays
The indicated GC cells were plated in 0.2% (w/v) agarose with a base

markers as well as to develop novel therapeutic strategies in GC

layer of 0.5% (w/v) agarose. Both layers contained complete me‐

treatment. In this work, we aimed to identify the signaling path‐

dium. After 2 weeks, colonies were counted by using a light micro‐

way controlling YAP1 stabilization and the regulatory function and

scope at 4× magnification with a numerical aperture 0.10 objective

mechanism of YAP1 in the Hippo pathway, which can be exploited

lens (ECLIPSE 80i; Nikon).

for potential therapeutic interventions.
Here, we report that STUB1 regulates GC cell proliferation
and response to therapeutic drugs through the YAP1 protein.

2.4 | Coimmunoprecipitation

Mechanistically, we found that STUB1 is the E3 ligase responsible

Cells were harvested and washed with PBS. Cells were then lysed

for YAP1 ubiquitination at K280 and degradation. Downregulation

with NETN buffer (20 mmol/L Tris‐HCl, pH 8.0, 100 mmol/L NaCl,

of STUB1 promoted GC proliferation, tumorigenesis, and chemore‐

1 mmol/L EDTA, and 0.5% Nonidet P‐40) containing 50 mmol/L b‐

sistance in a YAP1‐dependent manner. Furthermore, YAP1 overex‐

glycerophosphate, 10 mmol/L NaF, and 1 mg/mL each of pepstatin

pression was observed in gastric cancers, and was correlated with

A and aprotinin. Whole cell lysates obtained by centrifugation were

low expression of STUB1, suggesting that the STUB1‐YAP1 axis

incubated with 2 μg of the indicated Ab and protein A or protein

might have a role in the pathogenesis of GCs.

G Sepharose beads (Amersham Biosciences) for 4 hours at 4°C.

|
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After washing with NETN buffer 3 times, immunocomplexes were

Jinan University. A total of 1 × 10 6 MGC803 cells stably express‐

separated by SDS‐PAGE. Immunoblotting was carried out following

ing control shRNA, shSTUB1, or shSTUB1 with shYAP1 were in‐

standard procedures.

jected s.c. into female BALB/c nude mice. Every 4 days, the tumor
volumes were measured following a standard protocol. Data were

2.5 | Protein identification by mass spectrometry

analyzed using ANOVA. Following the blinding procedures, 2 per‐
sons undertook all the mouse experiments as a study group. Dr.

Flag‐tagged YAP1 or empty control lentiviral vector was transduced

Song‐Hui Xu injected the cells into the mice and Dr. Dong‐e Tang

into MGC803 cells in five 15‐cm dishes. Immunoprecipitation of

measured the tumors and analyzed the data. All protocols involving

Flag‐YAP1 was carried out as described above. The precipitated pro‐

live mice were approved by the Animal Care and Use Committee

teins were eluted with 3× flag peptides. The eluted samples were

of Jinan University. Mice were killed when the standard situations

subjected to in‐solution trypsin digestion, followed by liquid chro‐

occurred.

matography‐MS analysis and protein identification was undertaken
using the Mascot (version 2.3.02) program and compared against
the UniProt human protein database (released December 2014). The

2.9 | Statistical analysis

following search parameters were used: proteins were digested by

Data for the cell proliferation and colony formation assays are pre‐

trypsin; 2 missed cleavages were allowed; carbamidomethylation

sented as the mean ± SEM of 3 independent experiments. Data for

was set as the fixed modification, whereas oxidation (M) was con‐

the xenograft tumor growth study are presented as the mean ± SD

sidered the variable modification; an initial mass deviation of the

of 6 mice. A 2‐tailed, unpaired Student's t test, ANOVA, and χ2 test

precursor ion and fragment ions of up to 30 ppm and 0.1 Da, re‐

were utilized for statistical analyses (*P < .05; **P < .01).

spectively, were allowed; the false discovery rate was set at 1%; the

Supplementary materials and methods in Appendix S1.

protein score was set at R ≥ 40 and the number of unique peptides
was set at R ≥ 2.

2.6 | In vivo ubiquitination assay
This procedure was carried out as previously described. 21 Briefly,

3 | R E S U LT S
3.1 | STUB1 is a YAP1 binding protein and
destabilizes YAP1

cells were cotransfected with the indicated plasmids for 24 hours,

The Hippo pathway has been implicated in suppressing tissue

and were treated with 10 μmol/L MG132 for the indicated number

overgrowth and tumor formation by inhibiting the oncogenic ac‐

of hours prior to harvesting. Cells were lysed in RIPA buffer con‐

tivity of YAP1. 22 The dysregulation of the Hippo/YAP1 pathway

taining protease inhibitor cocktail (Roche). Flag‐YAP1 was immu‐

is involved in cancer development.11,23,24 However, the ubiqui‐

noprecipitated using anti‐Flag Abs and protein A/G agarose beads.

tin ligase that regulates YAP1 protein stability in human cancers

Polyubiquitinated YAP1 was detected using anti‐HA or anti‐ub Abs.

remains largely unknown. To identify YAP1‐interacting ubiqui‐
tinases, we used cells stably expressing Flag‐YAP1 to undertake

2.7 | Immunohistochemistry

tandem affinity purification and mass spectrometry analysis; sev‐
eral proteins were identified, including 4 ubiquitin ligases (RNF4,

Normal GC tissue samples and gastric tumor tissue samples were

WWP1, STUB1, and CBX4), as YAP1 interactors (Figure 1A). To

collected at Clinical Medical College of Jinan University. Tissue

confirm which ubiquitin ligase is responsible for YAP1 degrada‐

sample collection was approved by the Internal Review and Ethics

tion, we first examined the effects of these 4 ubiquitin ligases on

Boards of Jinan University. Tissue microarray chips containing

YAP1 expression. We stably expressed shRNAs targeting these

normal gastric tissue samples and GC tumor tissue samples were

proteins individually in the MGC803 human GC cell line (Figure

obtained from Shanghai OUTDO Biotech. Immunohistochemical

S1A). Only one, STUB1, significantly increased endogenous YAP1

staining and quantification were undertaken as described previ‐

protein expression (Figure 1B). Then we investigated the inter‐

ously. 21 The immunostaining was blindly scored by pathologists.

action between STUB1 and YAP1. Immunoblotting assays in the

The immunohistochemical score was calculated as described previ‐

coimmunoprecipitation experiment showed that endogenous

ously. 21 The χ2 test and Pearson's correlation coefficient were used

YAP1 coimmunoprecipitated with endogenous STUB1 (Figure 1C).

for statistical analysis of the correlation between STUB1 and YAP1

STUB1 is a cochaperone protein and E3 ubiquitin ligase that regu‐

expression.

larly interacts with the molecular chaperones Hsc70‐Hsp70 and
Hsp90 through its TPR domain, whereas its E3 ubiquitin ligase ac‐

2.8 | Athymic nude mouse tumor formation assay

tivity is restricted to the U‐box domain. 25,26 To determine which
domain of STUB1 is responsible for the STUB1‐YAP1 interaction,

Six‐week‐old female BALB/c nude mice were obtained from the

we coexpressed full‐length STUB1 with TPR domain, U‐box do‐

Model Animal Research Center of Jinan University and housed

main, and the middle region between TPR domain and U‐box do‐

under pathogen‐free conditions in the animal experiment center of

main fragments of STUB1 in 293T cells. Coimmunoprecipitation
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F I G U R E 1 STUB1 binds and destabilizes Yes‐associated protein 1 (YAP1). A, List of YAP1‐associated ubiquitin ligase proteins identified
by mass spectrometric analysis. MGC803 cells stably expressing Flag‐YAP1 were generated and YAP1 complexes were subjected to mass
spectrometric analysis. B, MGC803 cells stably expressing control (Ctrl) or the indicated shRNAs and western blot analysis were performed
with anti‐YAP1 Ab. C, MGC803 cell lysates were subjected to immunoprecipitation (IP) with control IgG, anti‐STUB1 (left panel), or anti‐
YAP1 Ab (right panel). The immunoprecipitates were then blotted with the indicated Abs. D, 293T cells were transfected with myc‐tagged
YAP1 and Flag‐tagged STUB1 fragments for 24 h, and lysates were subjected to immunoprecipitation with anti‐Flag M2 beads. Bound
proteins were analyzed by western blotting with Myc or Flag Abs. E, The indicated cells were untreated or treated with MG‐132 and western
blotting was carried out to examine the indicated protein levels. F, MGC803 cells stably expressing Ctrl or Flag‐STUB1 were subjected to
western blotting to examine the indicated protein. G, Cycloheximide (CHX) pulse‐chase assay was carried out in cells as in (F). Right panel,
protein levels of YAP1 relative to β‐actin. Results in (B) and (C) are shown as ± SEM of 3 independent experiments. TPR, tetratricopeptide
repeat

and western blot analysis revealed that the TPR domain of STUB1

YAP1 level was reversed by the addition of the proteasome inhibi‐

interacted with YAP1 (Figures 1D and S1B). Next, we investigated

tor MG132, suggesting that STUB1 regulates the YAP1 level in a

whether the binding of STUB1 to YAP1 requires the molecular

proteasome‐dependent manner (Figure 1E). Next, when we over‐

chaperone Hsp90. As shown in Figure S1D,E, the decrease in the

expressed STUB1 in 2 GC cell lines, we found that STUB1 upregu‐

YAP1 level was significantly reversed by knockdown or inhibition

lation decreased the YAP1 protein level (Figure 1F), with no effect

of Hsp90, suggesting that STUB1 might need the molecular chap‐

on the YAP1 mRNA level (Figure S1C). We then hypothesized that

erone Hsp90 to facilitate TPR domain‐dependent ubiquitination

STUB1 might regulate YAP1 stability, and we treated cells with

of YAP1. In addition, we examined whether the Hippo‐resistant

CHX and determined the half‐life of YAP1. As shown in Figure 1G,

YAP mutant (YAP‐5SA) could be regulated by STUB1. As shown in

YAP1 stability was dramatically decreased in STUB1‐overexpress‐

Figure S1F, we found that overexpression of STUB1 reduced levels

ing cells. In addition, we found that the half‐life of STUB1 was ap‐

of both the WT YAP1 and mutant YAP1 (YAP1‐5SA). As STUB1 is

proximately 14 hours (Figure S1G). Taken together, these results

a ubiquitination enzyme, we hypothesized that STUB1 might regu‐

indicate that STUB1 binds and destabilizes YAP1 through its TPR

late the protein level of YAP1. First, we found the decrease in the

domain, which needs the molecular chaperone Hsp90 to facilitate.

TANG et al.
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F I G U R E 2 STUB1 promotes K48‐linked ubiquitination of Yes‐associated protein 1 (YAP1) at the K280 site. A, 293T cells were
transfected with Myc‐STUB1, Flag‐YAP, and HA‐tagged ubiquitin plasmid (HA‐ub) as indicated. The polyubiquitylated YAP1 proteins
were detected by anti‐HA Ab. B, Cells stably expressing control or STUB1 shRNAs were subjected to ubiquitination assay and the
polyubiquitylated YAP1 proteins were detected by anti‐ub Ab. C, Cells transfected with Flag‐YAP1 were treated with or without 17‐AGG.
The polyubiquitylated YAP1 proteins were examined as in (B). D, 293T cells were transfected with Myc‐STUB1, Flag‐YAP1 (WT, K102R
mutant, K181R mutant, K204R mutant, K280R mutant, and K342R mutant), and HA‐ub. The analysis was undertaken as described for (A). E,
293T cells were transfected with Myc‐STUB1, Flag‐YAP1, and HA‐ub (WT, K6R mutant, K11 mutant, K27 mutant, K29 mutant, K33 mutant,
K48 mutant, and K63 mutant). The analysis was undertaken as described for (B). IP, immunoprecipitation

3.2 | STUB1 ubiquitinates YAP1 at K280 through
K48‐linked polyubiquitination
We next examined whether STUB1 regulates the level of YAP1

of YAP1 (Figure 2B). Several studies have reported that the T246M
mutation of STUB1 abolishes its ubiquitin ligase activity.27-29 To test
whether STUB E3 ligase activity is required for YAP1 ubiquitination,
we transfected 293T cells with STUB1 (WT or T246M mutant). We

ubiquitination in cells. As shown in Figure 2A, STUB1 overexpres‐

found that the T246M mutation of STUB1 did not increase YAP1

sion resulted in a significant increase in YAP1 polyubiquitination.

ubiquitination (Figure S2A), suggesting that STUB E3 ligase activity

Conversely, knocking down STUB1 decreased the polyubiquitination

is indispensable for YAP1 ubiquitination. To test whether STUB1 can

3150
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F I G U R E 3 STUB1 regulates cell proliferation and tumor growth through Yes‐associated protein 1 (YAP1). A, B, MGC803 cells stably
expressing control (Ctrl) or Flag‐STUB1 plasmids together with or without YAP1 shRNAs were subjected to western blotting to detect
the indicated protein levels. YAP1‐regulated target transcription genes were detected by quantitative RT‐PCR. Data were normalized to
the β‐actin mRNA (mean ± SD, n = 3). *P < .05; **P < .01. C, MGC803 cells stably expressing Ctrl or Flag‐STUB1 plasmids with or without
Flag‐STUB1 plasmids were subjected to western blotting to detect the indicated protein levels. D, Left: colony formation abilities of the cells
generated as above were measured after 2 wk. Colony numbers of cellular clones with more than 100 cells was measured (mean ± SEM of
3 independent experiments). Right: statistical analyses were carried out with ANOVA. *P < .05; **P < .01. E, Left: the cells described above
and were maintained in soft agar for 3 wk, and colony number per field was determined. Right: statistical analyses were carried out with
ANOVA. *P < .05; **P < .01. F‐H, Cells stably expressing Ctrl or shSTUB1 RNAs with or without shYAP1 RNAs were injected into athymic
nude mice, as described in the Method 2.8. Tumor growth was measured every 4 d. Images (G) and weight (H) of xenograft tumors are
shown (mean ± SD of 6 mice). All of the statistical analyses were carried out with ANOVA. *P < .05; **P < .01
directly ubiquitinate YAP1, we carried out the in vitro ubiquitination

WT GST‐STUB1 could directly ubiquitinate His‐YAP1 in the in vitro

assay using the purified His‐YAP1, GST‐STUB1 (WT or T246M mu‐

reaction, but not the T246M mutant. 17‐AAG is a heat shock protein

tant) and E1/E2/ubiquitin. His‐YAP1 was precipitated and analyzed

inhibitor that shows antitumorigenic and antiangiogenic properties

by western blotting with ubiquitin Abs. As shown in Figure S2B, the

in vitro and in in vivo animal models.30,31 Heat shock proteins can

|
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promote the ubiquitination and degradation of proteins through
cooperative interaction with the E3 ubiquitin ligase STUB1.

32
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STUB1 overexpression significantly reversed the effect of STUB1

Here,

overexpression (Figure 3C‐E, column 3 vs column 4). Conversely,

we used 17‐AAG to treat cells and found significantly reduced YAP1

we reduced YAP1 expression in MGC803 cells with STUB1 silenc‐

ubiquitination (Figure 2C). To identify the specific lysine sites in the

ing (Figure S3A) and examined cell proliferation and anchorage‐in‐

YAP1 protein with ubiquitination modification, we used UbPred

dependent growth. We found that STUB1 knockdown markedly

software (http://www.ubpred.org/). Five potential ubiquitination

increased the proliferation (Figure S3B) and anchorage‐independent

sites at lysine residues were found in the YAP1 protein (Table S1).

growth (Figure S3C) of MGC803 GC cells, whereas downregulation

We subsequently generated YAP1 mutants in which these lysine

of YAP1 could significantly reverse the effect of STUB1 knockdown.

residues were replaced with arginines. First, we found that STUB1

To investigate the biological function of the STUB1‐YAP1 inter‐

overexpression increased the polyubiquitination levels in the K102R,

action in GC cells in vivo, we used a xenograft gastric tumor model

K181R, K204R, and K342R YAP1 mutants but not in the K280R YAP1

in which the indicated numbers of MGC803 cells were injected

mutant (Figure 2D). Second, STUB1 overexpression did not decrease

into athymic nude mice and tumor growth was monitored. Mice

the protein levels of the K280R YAP1 mutant compared with those

implanted with STUB1 shRNA‐expressing MGC803 cells showed

of the other four YAP1 mutants (Figure S2C). To further confirm that

increased tumor growth throughout the experiment compared

K280 is a critical residue that regulates STUB1 mediated YAP1 deg‐

with that in mice implanted with control shRNA‐expressing cells

radation, we treated cells with CHX and determined the half‐life of

(Figure 3F). At 23 days after tumor cell implantation, we observed

WT YAP1 and K280R YAP1 mutant after transfection with STUB1.

a more than 2.5‐fold increase in the volume (Figure 3F) and a 2‐fold

As shown in Figure S2D, the K280R YAP1 mutant was more stable

increase in the weight of the tumors formed by STUB1‐depleted

than the WT YAP1. Furthermore, we found that STUB1 overexpres‐

MGC803 cells (Figure 3G,H). Notably, silencing of YAP1 in MGC803

sion increased the polyubiquitination levels in the WT, K6R, K11R,

cells expressing STUB1 shRNA fully reversed the tumor‐promoting

K27R, K29R, K33R, and K63R HA‐ubiquitin mutants but not in the

effect of STUB1 shRNA (Figure 3F‐H). Taken together, these findings

K48R mutant (Figure 2E) and the cells transfected the plasmid of

indicate that the loss of STUB1 promotes tumorigenesis through the

K48R HA‐ubiquitin could partially increase the YAP1 expression

upregulation of YAP1.

caused by transfection of WT HA‐ubiquitin (Figure S2E), suggesting
that YAP1 as a novel target of STUB1‐mediated K48‐linked ubiqui‐
tin. Taken together, these results suggest that STUB1 ubiquitinates
YAP1 at the K280 site by K48‐linked polyubiquitination.

3.4 | STUB1 is downregulated in human gastric
tumors and correlates with the YAP1 protein level
As a downstream effector, YAP1 plays a key role in the Hippo path‐

3.3 | STUB1 regulates cell proliferation and tumor
growth through the YAP1 pathway

way to control tissue overgrowth and tumor formation. YAP1 has
primarily been reported as an oncoprotein; elevated expression
and nuclear localization of YAP1 have been frequently observed in

We asked whether STUB1 functions as a tumor‐suppressing pro‐

human cancers.7,33-39 Posttranscriptional and posttranslational reg‐

tein by regulating YAP1. First, we assessed the effect of STUB1 on

ulation of YAP1 have been reported to contribute substantially to

YAP1 transactivation. We overexpressed STUB1 in MGC803 cells

the development of human cancer.10,40-42 As YAP1 plays a key role

with YAP1 silencing (Figure 3A) and examined the transcription of

in human cancer development, it is possible that in human cancers

YAP1‐regulated target genes (ANKRD1, Cyr61, and CTGF). As shown

STUB1 promotes the ubiquitination and destabilization of YAP1.

in Figure 3B, silencing YAP1 dramatically decreased the transcrip‐

First, we measured the expression of STUB1 and YAP1 in GC cell

tion of ANKRD1, Cyr61, and CTGF (column 1 vs column 3) and STUB1

lines and cancer tissue samples. As shown in Figure 4A, low STUB1

overexpression also reduced the transcription of YAP1‐regulated

protein levels correlated with high YAP1 expression in these GC cells

target genes (column 1 vs column 2), whereas STUB1 overexpres‐

compared with normal gastric epithelial GES‐1 cells. Furthermore,

sion did not show any additional effect in YAP1‐depleted cells (col‐

low STUB1 protein levels correlated with increased YAP1 expres‐

umn 3 vs column 4). These results suggest that STUB1 regulates

sion in most GC samples (Figure 4B). To determine the relevance

YAP1‐dependent transcription. To investigate the biological func‐

of YAP1 regulation by STUB1 in patients, we undertook immuno‐

tion of STUB1 in YAP1‐dependent cells, we evaluated prolifera‐

histochemical staining of YAP1 and STUB1 (Figure 4C) in GC tissue

tion and anchorage‐independent growth of STUB1‐overexpressing

microarrays. Notably, downregulation of STUB1 expression and

cells following the upregulation of YAP1 expression in these cells

high YAP1 expression were observed in 67.9% (72/106) and 74.5%

(Figure 3C). We observed that YAP1 overexpression markedly in‐

(79/106) of gastric tumors, whereas only 27.3% (6/22) and 31.8%

creased both the proliferation (Figure 3D, column 1 vs column 2)

(7/22) of normal mammary tissues showed low STUB1 expres‐

and anchorage‐independent growth (Figure 3E, column 1 vs col‐

sion and high YAP1 expression (Figure 4D), respectively, suggest‐

umn 2) of MGC803 GC cells. Conversely, STUB1 overexpression

ing that STUB1 was downregulated but YAP1 was upregulated in

decreased both the proliferation (Figure 3D, column 1 vs column 3)

human gastric tumors. Moreover, a significant negative correlation

and anchorage‐independent growth (Figure 3E, column 1 vs column

(R = −0.305, P < .001) between the STUB1 and YAP1 protein levels

3) of MGC803 GC cells, whereas restoration of YAP1 in cells with

was observed in these gastric carcinomas: 84.7% (61/72) of tumors
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F I G U R E 4 Yes‐associated protein 1 (YAP1) expression negatively correlates with STUB1 expression in clinical gastric cancer (GC)
samples. A, Expression of STUB1 and YAP1 in GES‐1 (normal gastric epithelial cell line) and the GC cell lines as indicated. B, A subset of the
GC tumor and normal tissues were subjected to western blotting, to examine the STUB1 and YAP1 protein levels. C, Representative staining
of STUB1 and YAP1 in GC and normal gastric tissues. D, Quantification of STUB1 and YAP1 protein levels in normal tissue and GC, and the
correlation study of STUB1 and YAP1 expression level in GC. Statistical analyses were undertaken with the χ2 test, P < .001. R, Pearson's
correlation coefficient

with low STUB1 expression also displayed high YAP1 expression

malignancies.10,44-46 We next examined whether STUB1 plays a role

(Figure 4D). However, it should be noted that 16.98% (18/106) of all

in the response of GC to chemotherapy. To investigate the role of

tumor specimens had high YAP1 expression but high STUB1 expres‐

STUB1 in the response of GC to chemotherapy, MGC803 cells stably

sion (Figure 4D). Collectively, these data suggest that loss of STUB1

expressing YAP1 shRNAs, which responded to mitomycin C, cispl‐

might contribute to upregulation of YAP1 in a substantial fraction of

atin, and etoposide, were subsequently treated with either vehicle

human gastric tumors, whereas in other gastric tumors, YAP1 can be

or 17‐AAG. As shown in Figure 5A, we found that 17‐AGG inhib‐

activated by different mechanisms, including genetic alterations and

ited YAP1 degradation. In addition, cells treated with 17‐AAG were

43

upregulation of YAP1 deubiquitinases such as USP7

10

and USP9X.

significantly resistant to chemotherapy, whereas YAP1 knockdown
promoted cellular chemosensitivity (Figure 5B). However, 17‐AAG

3.5 | STUB1 regulates the response of GC cells to
chemotherapy through YAP1

treatment of cells with stable expression of YAP1 shRNAs reversed
the sensitivity to chemotherapy (Figure 5B). Similarly, silencing of
STUB1 in SGC7901 cells using 2 specific shRNAs significantly in‐

We found that STUB1 negatively regulates the expression of

creased the YAP1 protein levels (Figure 5C) and increased cell resist‐

YAP1, which plays a key role in chemoresistance in different

ance to mitomycin C, cisplatin, and etoposide (Figure 5D), whereas

|
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F I G U R E 5 STUB1‐Yes‐associated protein 1 (YAP1) axis regulates gastric cancer cells’ response to chemotherapy. A, MGC803 cells
stably expressing the indicated constructs were treated with either vehicle or 17‐AGG for 24 h and were then subjected to western blot
analysis to examine the indicated protein levels. B, As in (A), cells were treated with mitomycin, cisplatin, and etoposide, and cell survival
was determined (mean ± SD, n = 3). C, SGC7901 cells stably expressing control (Ctrl) or STUB1 shRNA with or without YAP1 shRNA were
subjected to western blotting to detect the indicated protein levels. D, As in (C), cells were treated with mitomycin, cisplatin, and etoposide,
and cell survival was measured (mean ± SD, n = 3). E, Schematic representation of how STUB1 regulates YAP1

YAP1 knockdown in STUB1‐depleted cells reversed the sensitivity

degradation of YAP1. STUB1 is an E3 ubiquitin ligase that mediates

to chemotherapy (Figure 5D). These results establish an important

K48‐linked polyubiquitination of YAP1 at K280.

role for STUB1 in regulating the chemotherapeutic response in GC
through YAP1 signaling.

YAP1, a major factor in the Hippo pathway controls multiple cel‐
lular processes related to proliferation and apoptosis, and its dysreg‐

In summary, we showed that STUB1 interacts with YAP1 and

ulation has been linked to various cancers.10 Here, we found that the

promotes its ubiquitination, ultimately leading to YAP1 degradation

human YAP1 protein levels were significantly increased in GC tissues

(Figure 5E). We revealed STUB1 as a negative regulator of YAP1

compared with those in normal gastric tissues. Our data consistently

in GC cell proliferation and as a potential biomarker for predicting

supported the reports that YAP1 functions as a potential oncogene

chemoresistance.

and is associated with the prognosis of many human cancers in‐
cluding prostate, breast, ovarian, and hepatocellular cancers.11,47-49

4 | D I S CU S S I O N

Silencing YAP1 significantly suppressed GC proliferation and tumor‐
igenesis, indicating that YAP1 could be a novel therapeutic target in
GC. Our findings suggest that YAP1 could be a novel independent

Our study found that YAP1 promoted GC proliferation in vitro and

prognostic factor in GC patients.

in vivo, and we elucidated a novel mechanism underlying the effect

The process of ubiquitination is triggered by the coordinated

of STUB1 on cancer progression. Specifically, we revealed the inter‐

action of 3 classes of enzymes, including E1 ubiquitin activating

action of STUB1 with YAP1 and the subsequent ubiquitination and

enzymes, E2 ubiquitin‐conjugating enzymes, and E3 ubiquitin
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ligases. Among these enzymes, the E3 ligase determines the sub‐
strate specificity of the process. The STUB1 protein (the carboxy
terminus of the Hsc70‐interacting protein), composed of a TPR
domain at its amino terminus that interacts with chaperone pro‐
teins (Hsc70, Hsp70, and Hsp90) and a U‐box domain at its car‐
boxy terminus with E3 ubiquitin ligase activity, functions as a link
between the chaperone and proteasome systems. 50,51 Numerous
reports have indicated that STUB1 acts as a tumor suppressor
because it induces the ubiquitination and degradation of several
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oncogenic proteins, such as mutant p53, 51 SRC‐3, 52 Smad3, 53
c‐ErbB2/neu, 54 Dbl, 55 Runx1, 56 hypoxia‐inducible factor‐1a, 57
the estrogen receptor, 58 and the Met receptor. 59 A recent study
showed that STUB1 expression is significantly decreased in GC
lesions compared with that in paired noncancerous tissues, and
that this decrease might be associated with STUB1 promoter
methylation in GC cells.
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Thus, identifying novel substrates is

essential for understanding STUB1 biology and its implications
in GC progression and drug resistance. Here, we found that the
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TPR domain of STUB1 interacts with YAP1 and promotes K48‐
linked polyubiquitination of YAP1 at K280. This finding explains
why this E3 ligase accounts for YAP1 ubiquitination; several
studies have reported that YAP1 undergoes deubiquitinase‐me‐
diated stabilization
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but have not identified which E3 ligase

mediates YAP1 ubiquitination. The mechanisms through which
E3 ubiquitin ligases and deubiquitinases balance YAP1 expres‐
sion could explain why the activity of YAP1 is tightly regulated
under physiological conditions, whereas elevated YAP1 activity
and/or overexpression has been observed in different cancer
types.11
STUB1 reportedly induces the degradation of MST1, an up‐
stream inhibitor of YAP, in an Hsp70‐interacting protein (CHIP)‐
dependent manner under different stresses and in different kinds
of cancer. 62,63 This regulation seems to be the opposite of YAP1
activity, because we found that the interaction of STUB1 with
YAP1 and subsequent ubiquitin and degradation of YAP1 pro‐
ceeds in an Hsp90‐dependent manner. Future studies are needed
to determine whether STUB1 regulates MST1 degradation in GC
cancer.
In summary, we revealed a connection between STUB1 and the
Hippo pathway in GC. In this study, we demonstrated that STUB1
may target YAP1 for ubiquitin and destabilization, thereby inhibit‐
ing GC growth and tumor progression. The tumor suppressor role
of STUB1 was partially reversed by inhibition of YAP1 activity in
vitro and in vivo. Interestingly, STUB1 expression was negatively
correlated with YAP1 protein expression in GCs. Our study provides
evidence that inhibition of YAP1 activity could be used to sensitize
cancer cells to radiotherapy and chemotherapy, although the clinical
effect of YAP1 inhibitors needs further testing. Furthermore, our
findings indicate that YAP1 ubiquitination and degradation mediated
by the E3 ligase STUB1 ubiquitin and degradation affects the re‐
sponse to chemotherapeutic agents, which has broader implications
for the treatment of other cancers and should be investigated in the
future.
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